What's Next For HIMS Stock?

Hims & Hers (HIMS) stock fell 13% after Q2 results, despite 73% revenue growth to $544.8 million and strong profitability gains with adjusted EBITDA doubling to $82 million and EPS beating estimates, because revenue missed consensus forecasts. The company's reliance on compounded GLP-1 sales continues to drive growth but introduces significant regulatory and competitive risks, as evidenced by the terminated Novo Nordisk partnership. Even after the decline, HIMS maintains premium valuations compared to the S&P 500 and analyst targets, suggesting potential further downside risk given the regulatory uncertainty and high cost for growth.

Analysis

Hims & Hers (HIMS) experienced a significant 13% after-hours stock decline, driven by a Q2 revenue miss despite otherwise strong performance metrics. The company reported revenue of $544.8 million, a robust 73% year-over-year increase, but this fell short of the $552 million consensus estimate, signaling a potential deceleration in its growth trajectory. In contrast, profitability showed marked improvement, with adjusted EBITDA more than doubling to $82 million and earnings per share of $0.17 comfortably beating the $0.15 analyst forecast. The core of the market's concern lies in the company's strategic reliance on compounded GLP-1 medications, which fuels its growth but introduces substantial regulatory and competitive risk. This vulnerability was previously highlighted by a brief, terminated partnership with Novo Nordisk. Even after the price drop, HIMS maintains premium valuation multiples—including a Price-to-Earnings ratio of 74.7x versus the S&P 500's 22.8x—while its stock price of approximately $55 remains above the average analyst price target of $50, indicating that the market may still be pricing in a level of growth that is increasingly uncertain.

Key Decisions for Investors

• Investors should closely monitor for any increased regulatory scrutiny or legal challenges from established pharmaceutical firms regarding compounded drugs, as this poses a direct threat to Hims & Hers' primary growth engine.
• Given that the stock continues to trade at premium valuation multiples and above the average analyst price target even after the recent drop, it may be prudent to wait for a more attractive entry point that better reflects the inherent business model risks.
• The combination of a revenue miss and high dependence on a legally contentious product category suggests that current holders might consider trimming positions to lock in gains and reduce exposure to potential regulatory headwinds.